title: Fluorescence in situ hybridization analysis of chromosome aberrations in 60 Chinese patients with multiple myeloma.
abstract: Conventional cytogenetic analysis is often hampered owing to the low mitotic index of multiple myeloma (MM) cells in bone marrow samples of MM. Interphase fluorescence in situ hybridization (I-FISH) analysis combined with magnetic-activated cell sorting (MACS) has substantially enhanced the sensitivity of cytogenetic analysis. Here, we used I-FISH to explore the incidence of chromosomal abnormalities in 60 Chinese patients with newly diagnosed MM. Five different specific probes for the regions containing 13q14.3 (D13S319), 14q32 (IGHC/IGHV), 1q21, 1p12, and 17p13 were used to detect chromosomal aberrations, and LSI IGH/CCND1, LSI IGH/FGFR3, and LSI IGH/MAF probes were further applied to detect t(11;14)(q13;q32), t(4;14)(p16;q32), and t(14;16)(q32;q23) in patients with 14q32 rearrangement. Fifty of the patients (83.3%) had at least one type of abnormalities regarding the regions analyzed. Nine patients (15%) had one abnormality; 10 patients (16.7%) had two abnormalities; 31 patients (51.7%) had three or more abnormalities. The most frequent abnormality in the patients was illegitimate IgH rearrangement (70%), followed by 13q14 deletion (63.3%), 1q21 amplification (61.7%), 1p12 deletion (33.3%), and 17p13 deletion (13.3%). These aberrations are not randomly distributed, but strongly interconnected. Patients with 17p13 deletion or t(4;14)(p16;q32) had significant higher β2-microglobulin level (P < 0.05). However, all these abnormalities had no correlation with age, gender, disease stage, and Ig isotype; yet, it was showed that the frequencies of the individual chromosomal abnormalities were very high. Taken together, MACS in combination with I-FISH may be a promising tool to detect the molecular cytogenetic abnormalities of MM.
authors: Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 300 Guangzhou Road, Nanjing 210029, China.
authors: Xiao
authors: X
authors: Gao
authors: Chunming
authors: C
authors: Li
authors: Run
authors: R
authors: Zhang
authors: Ruifang
authors: R
authors: Yang
authors: Xiaoyan
authors: X
authors: Qu
authors: Hairong
authors: H
authors: Qiu
authors: Jiaren
authors: J
authors: Xu
authors: Hua
authors: H
authors: Lu
authors: Jianyong
authors: J
authors: Li
authors: Lijuan
authors: L
authors: Chen
references: Cancer Res. 1995 Sep 1;55(17):3854-9
references: 7641204
references: Blood. 2005 Jan 1;105(1):358-60
references: 15339849
references: Leuk Lymphoma. 2004 May;45(5):965-9
references: 15291356
references: Leukemia. 1995 Dec;9(12):2109-14
references: 8609724
references: Cancer Genet Cytogenet. 2006 May;167(1):20-5
references: 16682281
references: Br J Haematol. 2003 Jan;120(1):44-52
references: 12492575
references: Leukemia. 2010 Mar;24(3):623-8
references: 20072152
references: Blood. 2004 Jun 1;103(11):4056-61
references: 14982868
references: Leuk Lymphoma. 2006 May;47(5):803-14
references: 16753864
references: Leukemia. 2009 Dec;23(12):2210-21
references: 19798094
references: Bone Marrow Transplant. 2010 Jan;45(1):117-21
references: 19448682
references: Blood. 2008 Nov 15;112(10):4235-46
references: 18337559
references: Expert Rev Mol Diagn. 2007 Jul;7(4):453-9
references: 17620051
references: Leukemia. 2007 Apr;21(4):818-20; author reply 821
references: 17301817
references: Cancer Genet Cytogenet. 1999 Aug;113(1):73-7
references: 10459351
references: Blood. 2007 Mar 15;109(6):2276-84
references: 17105813
references: Blood. 2003 Feb 15;101(4):1520-9
references: 12393535
references: Mayo Clin Proc. 2010 Jun;85(6):532-7
references: 20511484
references: Br J Haematol. 2007 Feb;136(4):615-23
references: 17223915
references: Hematology. 2009 Apr;14(2):90-4
references: 19298720